Frazier Lifesciences Acquisition Corporation
Equities
NAMS
NL00150012L7
Biotechnology & Medical Research
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
17.8 EUR | -6.81% | -1.95% | +70.99% |
May. 16 | Transcript : NewAmsterdam Pharma Company N.V. - Special Call | |
May. 15 | TD Cowen Starts NewAmsterdam Pharma With Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+70.99% | 1.75B | |
+9.83% | 115B | |
+10.80% | 105B | |
-10.84% | 22.71B | |
-1.69% | 21.83B | |
-10.23% | 18.18B | |
-41.92% | 16.52B | |
-15.11% | 16.01B | |
+6.62% | 14.14B | |
+17.53% | 10.71B |
- Stock Market
- Equities
- NAMS Stock
- News Frazier Lifesciences Acquisition Corporation
- Scotiabank Starts NewAmsterdam Pharma With Sector Outperform Rating, $35 Price Target